AOD-9604 in Fasanò-Ss.Trinità-Pianello — Fat Loss Peptide Research Guide
AOD-9604 research guide for Fasanò-Ss.Trinità-Pianello. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 in Fasanò-Ss.Trinità-Pianello — Research & Sourcing Guide
For anyone in Fasanò-Ss.Trinità-Pianello looking to source AOD-9604, the foundational reality is that this compound is available only through an online research supply market. The practical advantage of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any physical store could provide. The core quality markers for AOD-9604 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Fasanò-Ss.Trinità-Pianello researchers need to know about finding, evaluating, and storing AOD-9604 for scientific research use.
Understanding AOD-9604 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Fasanò-Ss.Trinità-Pianello researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying AOD-9604: Quality Markers to Look For
Assessing AOD-9604 vendors starts with the COA: locate the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at minute levels. Community reputation in research forums is a valuable complement to COA verification — vendors with consistently positive reports over 12+ months have proved themselves through consistent results. Bacteriostatic water is the appropriate reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 30 days refrigerated.
Order AOD-9604 — ships to Fasanò-Ss.Trinità-Pianello
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and limited human studies. Reconstitute AOD-9604 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Endotoxin testing in the AOD-9604 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at minute levels, and no cost saving makes omitting this acceptable. PubMed represent the most comprehensive research databases for AOD-9604 research; prioritise peer-reviewed studies with characterised source material over conference abstracts or single case observations.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
